Ribavirin in the treatment of SARS: A new trick for an old drug?
摘要：
The dramatic outbreak of severe acute respiratory syndrome (SARS) has led to the use of high-dose intravenous and oral ribavirin in patients affected with this disorder. Ribavirin, a nucleoside analogue with broad antiviral activity, was discovered in 1970 by ICN Pharmaceuticals. In Canada, ribavirin is licensed for the treatment of respiratory syncytial virus (RSV) infection in infants and, in combination with interferon α2b, hepatitis C. In view of the limited circumstances in which it is prescribed, most physicians are not familiar with its pharmacology, dosing and safety. In this article we summarize this information for the benefit of health care professionals who may be involved with patients receiving ribavirin for treatment or prevention of SARS. We also review emerging data on the potential efficacy of ribavirin against the SARS virus, a new mutant of coronavirus.
展开
DOI：
doi:10.1001/jama.289.18.2432
被引量：
年份：
2003
EBSCO
万方医学
Europe PMC
NCBI
Oxford Univ Press
查看更多
Pubmed Central
(全网免费下载)
NCBI
Europe PMC
(全网免费下载)
ResearchGate
EBSCO
EBSCO
Citeseer
(全网免费下载)
highbeam.com
pherobase.com
nagasaki.med.or.jp
(全网免费下载)
学术范
core.kmi.open.ac.uk
schulich.uwo.ca
(全网免费下载)
mendeley.com
学术范
(全网免费下载)
pubfacts.com
mysciencework.com
jasn.asnjournals.org
cmaj.ca
(全网免费下载)
researchrepository.murdoch.edu.au
mmbr.asm.org
cmaj.ca
Pubmed Central
(全网免费下载)
Europe PMC
(全网免费下载)
Citeseer
(全网免费下载)
nagasaki.med.or.jp
(全网免费下载)
schulich.uwo.ca
(全网免费下载)
cmaj.ca
(全网免费下载)
学术范
(全网免费下载)
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
引用走势
站内活动
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
